Paclitaxel-Coated Balloon Found Superior in Femoropopliteal PAD

This article originally appeared here.
Share this content:
Paclitaxel-Coated Balloon Found Superior in Femoropopliteal PAD
Paclitaxel-Coated Balloon Found Superior in Femoropopliteal PAD

THURSDAY, June 25, 2015 (HealthDay News) -- For patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloon is associated with a superior rate of primary patency at 12 months versus angiography with a standard balloon, according to a study published online June 24 in the New England Journal of Medicine.

Kenneth Rosenfield, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a single-blind randomized trial at 54 sites. Four hundred seventy-six patients with symptomatic intermittent claudication or ischemic pain while at rest and angiographically significant atherosclerotic lesions were randomized in a 2:1 ratio to angioplasty with a paclitaxel-coated balloon or standard angioplasty.

The researchers found that the rate of primary patency at 12 months was superior among patients who had undergone angioplasty with the drug-coated balloon versus conventional angioplasty (65.2 versus 52.6 percent; P = 0.02). Overall, 83.9 and 79.0 percent of patients were free from primary safety events with the drug-coated balloon and standard angioplasty, respectively (P = 0.005 for noninferiority). No significant between-group differences were seen in functional outcomes, or in the rates of death, amputation, thrombosis, or reintervention.

"Treatment of femoropopliteal peripheral artery disease with a paclitaxel-coated balloon provided superior vessel patency through 12 months, as compared with a strategy of conventional percutaneous transluminal angioplasty with a standard balloon," the authors write.

The study was funded by Lutonix-Bard, manufacturer of the paclitaxel-coated balloon used in the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Dupilumab Reduces Rate of Severe Asthma Exacerbations

Dupilumab Reduces Rate of Severe Asthma Exacerbations

And, add-on dupilumab reduces glucocorticoid dose in patients with glucocorticoid-treated asthma

Better Social Support Network Protects Black Men Against HIV

Better Social Support Network Protects Black Men Against ...

Social networks of black men who have sex with men influence HIV risk behavior

Recommendations Developed for Managing Postpartum Pain

Recommendations Developed for Managing Postpartum Pain

Impact of medications on mother-infant dyad should be considered, as many women breastfeed

is free, fast, and customized just for you!

Already a member?

Sign In Now »